Article Sidebar
Published:
Nov 21, 2021Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of normodyne-magnesium sulfate combination treatment on pregnancy-induced hypertension, and its effect on VEGF and Flt-1 levels
Abstract
Purpose: To investigate the efficacy of the combined use of normodyne and magnesium sulfate in the treatment of pregnancy-induced hypertension, and its effect on vascular endothelial growth factor (VEGF) and factor receptor-1 (Flt-1) levels in serum.
Methods: A total of 100 patients with pregnancy-induced hypertension attending Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region, Xinjiang, China, were categorized as Group A, and then further subdivided into control sub-group (who were treated with magnesium sulfate only) and study sub-group (treated with magnesium sulfate plus normodyne). Furthermore, 100 healthy pregnant
women attending the hospital for prenatal examination during the same period were categorized as Group B. Serum expressions of VEGF and Flt-1 in all patients were determined and compared. The therapeutic effect, adverse reactions, adverse pregnancy outcomes, blood pressure before and after treatment, 24 h proteinuria, and serum expression levels of VEGF and Flt-1 in the study and control groups were determined and compared.
Results: Serum VEGF levels in patients with pregnancy-mediated hypertension were significantly lower than those of healthy pregnant women, and Flt-1 was raised in healthy pregnant women (p < 0.05). In the study group, treatment was markedly more effective, and the degree of amelioration of blood pressure, 24 h proteinuria, serum VEGF, and Flt-1 were significantly higher than for control sub-group. There were lower adverse pregnancy outcomes in study sub-group than in control (p < 0.05).
Conclusion: The combination of magnesium sulfate and normodyne produces greater clinical efficacy in the treatment of patients with pregnancy-induced hypertension than magnesium sulfate alone, and also shows a high safety profile.
